Dedicated to creating life-changing medicines for people with
limited or no options.

Research and Development

As the field of science has grown, so have our R&D capabilities. We actively explore revolutionary drug options ranging from small molecule advancements to biologics, and novel compounds within hematology/oncology and sleep medicine. This dynamic approach has allowed us to shepherd new medicines to market — from late-stage discovery through clinical development and regulatory approval.

All of these advancements are a reflection of our continued investment in an evolving and growing research and development focus.

Pipeline

PRE-CLINICAL
Oxybate
once-nightly dosing

CombiPlex
Solid tumors

CombiPlex

Asparaginase
Acute lymphocytic leukemia (ALL)/other hematological malignancies

Recombinant pegaspargase
hematological
malignancies

Defibrotide
Exploratory activities

Exosome NRAS
Hematologic malignancies§

Exosome STAT3
Hematologic malignancies§

Exosome candidates
Solid tumors/Hematologic malignancies§

PHASE 1
CPX-351 + gemtuzumab
R/R AML or HMA Failure
MDS*† (ages ≥18)

CPX-351 + venetoclax
Low intensity dosing for unfit AML†

IMGN779
R/R CD33 + Acute Myeloid Leukaemia (AML)

IMGN632
hematological malignancies

PHASE 2
Solriamfetol
EDS in Parkinson’s disease

Defibrotide
prevention of acute GvHD

Defibrotide
TA-TMA†

Defibrotide
CAR-T associated neurotoxicity†

CPX-351 + venetoclax
de novo or R/R AML**

CPX-351
MDS**†

CPX-351
R/R AML

PHASE 3
JZP-258
Cataplexy & EDS in narcolepsy

JZP-258
idiopathic hypersomnia

Defibrotide
prevention of VOD

CPX-351
AML or HR-MDS (AML19)**‡

CPX-351
AML or HR-MDS (AML18)**‡

REGULATORY
Solriamfetol EU
EDS in OSA or narcolepsy

Solriamfetol U.S.
EDS in OSA and narcolepsy

Sleep
Hematology / Oncology
Opt-in Opportunity
*Jazz & MD Anderson Cancer Center Study
** Key Cooperative Group Study
Planned
Study Sponsor – Cardiff University
§Jazz & Codiak BioSciences alliance
Jazz & ImmunoGen alliance

Through Jazz’s patented CombiPlex® platform, Jazz is evaluating oncology combinations to support identification of clinical product candidate(s) and is leading a collaborative approach with partners to research and develop new therapies.